We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The catechol-O-methyltransferase Val<sup>108/158</sup>Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.
- Authors
Szegedi, A.; Rujescu, D.; Tadic, A.; Müller, M. J.; Kohnen, R.; Stassen, H. H.; Dahmen, N.
- Abstract
The catechol-O-methyltransferase (COMT) is a major degrading enzyme in the metabolic pathways of catecholaminergic neurotransmitters such as dopamine and norepinephrine. This study investigated whether the functionally relevant Val108/158Met gene variant is associated with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized clinical trial with both drugs. In patients treated with mirtazapine, but not paroxetine, allelic variations in the COMT gene were associated with differential response. COMTVAL/VAL and COMTVAL/MET genotype carriers showed a better response than COMTMET/MET-bearing patients in the mirtazapine group. Moreover, carriers of the COMTVAL/VAL or COMTVAL/MET genotype had significantly greater HAMD-17 (Hamilton Rating Scale for Depression 17 item version) score reductions than COMTMET/MET homozygotes from week 2 to 6, respectively, in the mirtazapine group. Time course of response and antidepressant efficacy of mirtazapine, but not paroxetine, seem to be influenced in a clinically relevant manner by this allelic variation within the COMT gene.The Pharmacogenomics Journal (2005) 5, 49-53. doi:10.1038/sj.tpj.6500289 Published online 2 November 2004
- Subjects
PHARMACOGENOMICS; MEDICAL genetics; ANTIDEPRESSANTS; CATECHOL; NEUROTRANSMITTERS
- Publication
Pharmacogenomics Journal, 2005, Vol 5, Issue 1, p49
- ISSN
1470-269X
- Publication type
Article
- DOI
10.1038/sj.tpj.6500289